The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial.

Trials · 2023 · PMC9830619 · PMID 36627711

Europe PMC DOI

hedged sentence

0.0720

closest p · 1.4× alpha

0.0720

boldest claim

The sentences

did not reach statistical significancep =0.072so close (0.05 < p ≤ 0.1)

The least squares (LS) mean difference in change from baseline in PsA-modified vdH-S score vs placebo was statistically significant in the guselkumab Q4W group (LS mean difference (−0.66, p =0.011); however, this difference did not reach statistical significance with the Q8W dosing regimen vs placebo (LS mean difference −0.43, p =0.072).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.